NASDAQ:KOOL

Cesca Therapeutics (KOOL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$9.51
$9.62
50-Day Range
$2.11
$5.14
52-Week Range
$2.10
$7.00
Volume
16,634 shs
Average Volume
112,188 shs
Market Capitalization
$23.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KOOL stock logo

About Cesca Therapeutics Stock (NASDAQ:KOOL)

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

KOOL Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
See More Headlines
Receive KOOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cesca Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2018
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Laboratory Apparatus & Furniture
Sub-Industry
N/A
Current Symbol
NASDAQ:KOOL
Fax
N/A
Employees
53
Year Founded
N/A

Profitability

Net Income
$-39,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.67 million
Book Value
$3.11 per share

Miscellaneous

Free Float
N/A
Market Cap
$23.15 million
Optionable
Not Optionable
Beta
1.07
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Xiaochun Xu M.B.A. (Age 48)
    Ph.D., Chairman, CEO & Pres
  • Mr. Jeff Cauble (Age 46)
    Principal Financial & Accounting Officer
  • Mr. James Xu J.D. (Age 48)
    L.L.M., M.B.A., Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec.
  • Mr. Philip H. Coelho (Age 75)
    Chief Technology Officer
  • Ms. Haihong Zhu
    Pres of ThermoGenesis

KOOL Stock Analysis - Frequently Asked Questions

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) posted its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($0.27) earnings per share for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative trailing twelve-month return on equity of 77.30%.

What other stocks do shareholders of Cesca Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), NVIDIA (NVDA), QUALCOMM (QCOM), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD).

This page (NASDAQ:KOOL) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners